Drugs / BC001
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06773312 | Feb 2025 → Oct 2026 expected | gastroesophageal junction adenocarcinoma | Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BC001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06773312 ↗ |
| Route | Intravenous | “BC001 8mg/kg, 12mg/kg or 16mg/kg intravenously” NCT06773312 ↗ |